When we look at the Analyst Recommendations of the stock, the company has 1.67 rating given by Analysts where 1 stands for Strong Buy and 5 stands for Strong Sell.
Alder Biopharmaceuticals, Inc. (ALDR) average trading volume of 795,005 during the past month is 34.48% below its average volume over the past year, indicating that investors have been less active than usual in the stock in recent times. Royal Bank of Canada started coverage on shares of Alder BioPharmaceuticals in a report on Thursday, September 14th. They set an "outperform" rating and a $20.00 price target on the stock. BMO Capital Markets has "Buy" rating and $22.0 target. BidaskClub raised Alder BioPharmaceuticals from a sell rating to a hold rating in a research note on Thursday. Mizuho restated a buy rating and set a $32.00 price objective on shares of Alder BioPharmaceuticals in a report on Friday, September 15th. Canaccord Genuity assumed coverage on Alder BioPharmaceuticals in a research report on Thursday, October 26th. They issued a buy rating and a $20.00 price objective for the company. At present, 0 analysts call it Sell, while 1 think it is Hold. The company now has a consensus rating of "Buy" and an average target price of $27.71.
Shares of Alder BioPharmaceuticals (ALDR) opened at $12.95 on Tuesday. The company had a trading volume of 1,200,000 shares, compared to its average volume of 758,012. Alder BioPharmaceuticals has a one year low of $8.60 and a one year high of $25.45.
Currently, the stock carries a price to earnings ratio of 0, a price to book ratio of 2.64, and a price to sales ratio of 1296.16.
Alder BioPharmaceuticals (NASDAQ:ALDR) last released its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.92) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.21) by $0.29.
When the current quarter ends, Wall Street expects Netlist Inc.to have earnings per share of $-0.04.
In other news, insider Mark James Litton sold 16,520 shares of Alder BioPharmaceuticals stock in a transaction dated Monday, October 16th. With 720,100 shares average volume, it will take short sellers 10 days to cover their ALDR's short positions. Following the transaction, the insider now owns 116,452 shares in the company, valued at $1,435,853.16. Legal & General Group Plc now owns 15,496 shares of the biopharmaceutical company's stock valued at $177,000 after purchasing an additional 400 shares during the last quarter. The data from the past twelve months tells a similar story: insiders executed 5 buys and 8 sells, and ownership decreased by a net of 42210 shares. Quantitative Systematic Strategies LLC acquired a new position in Alder BioPharmaceuticals in the third quarter valued at $132,000. Legal & General Group Plc boosted its position in shares of Alder BioPharmaceuticals by 2.6% in the second quarter. SG Americas Securities LLC increased its stake in Alder BioPharmaceuticals by 109.4% in the second quarter.
Stephens Investment Management Group Llc decreased Advisory Brd Co (NASDAQ:ABCO) stake by 22,982 shares to 804,897 valued at $43.16 million in 2017Q3. Finally, Voya Investment Management LLC increased its stake in Alder BioPharmaceuticals by 8.4% in the second quarter. Voya Investment Management LLC now owns 22,304 shares of the biopharmaceutical company's stock valued at $255,000 after purchasing an additional 1,734 shares in the last quarter.
ILLEGAL ACTIVITY NOTICE: "Alder BioPharmaceuticals (ALDR) Lifted to "Sell" at ValuEngine" was originally published by Marea Informative and is the sole property of of Marea Informative.
Alder BioPharmaceuticals, Inc, is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize genetically engineered therapeutic antibodies with the potential to meaningfully transform current treatment paradigms.